On July 7, 2026 Imugene Limited ("Imugene", the "Company", "ASX:IMU") , a clinical-stage immuno-oncology company, reported it has received firm commitments from sophisticated, professional and institutional investors for a two-tranche placement to raise approximately $11.12 million (before costs) ( the "Placement") through the issue of approximately 117.1 million new fully paid ordinary shares ("New Shares") at an issue price of $0.095 per New Share ("Offer Price"). The Placement was strongly supported by new and existing institutional investors, including long-only global investors and a global pharmaceutical company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Placement includes a placement to Directors of Imugene to raise approximately $0.12m (before costs) through the issuance of ~1.3m New Shares ("Directors Placement") subject to shareholder approval. Managing Director and Chief Executive Officer, Leslie Chong said: "The first two evaluable patients in our concurrent BTKi combination cohort have both achieved complete responses, providing a strong early clinical signal for azer-cel in a therapeutic class worth more than US$12 billion annually. This Placement funds a series of important clinical data readouts over the next 6–12 months, including presentations at ASH (Free ASH Whitepaper) and ASCO (Free ASCO Whitepaper), while supporting our ongoing business development activities and continued discussions with potential pharmaceutical partners. We thank our shareholders, new investors and Directors for their ongoing support as we advance azer-cel towards a registrational pathway"
About the Placement
Under the terms of the Placement, the Company has secured firm commitments for approximately $11.1 million and proposes to issue approximately 117.1 million New Shares to Placement participants at an issue price of $0.095 per New Share, representing a discount of:
• 17.7% to the 30-day VWAP of $0.115 up to and including Thursday, 2 July 2026; and
• 29.6% to the last closing price of $0.135 on Thursday, 2 July 2026. Shares under the Placement will be issued as follows:
• Tranche 1 Placement to raise A$7.0 million (before costs) through the issuance of approximately 73.7 million New Shares ("Tranche 1 Placement") pursuant to the Company’s placement capacity under Listing Rules 7.1 and 7.1A; and
• Tranche 2 Placement to certain investors, including Directors of Imugene to raise $4.1m (before costs) through the issuance of 43.4m New Shares, with any shares in excess of the company’s placement capacity under Listing Rules 7.1 and 7.1A ("Tranche 2 Placement") and the issue of shares under the Directors Placement subject to shareholder approval at the EGM
Placement participants include an international, commercial-stage biopharmaceutical company, which subscribed for approximately 14% of the Placement, subject to shareholder approval.
(Press release, Imugene, JUL 7, 2026, View Source [SID1234669281])